EUVIMEDOpdag EUVIMED
Open access · CC BY-NC 4.0

Pre‐Treatment Concerns and Their Association With Functioning and Well‐Being During Incretin‐Based Therapy: A Cross‐Sectional Study

Ali Kapan iD, Tobias Brandl, Thomas Waldhör iD, Othmar Moser iD, Richard Felsinger

Diabetes, Obesity and Metabolism · 2026

DOI: 10.1111/dom.70599 ↗

At a glance

Journal article in Diabetes, Obesity and Metabolism, 2026. Written by Ali Kapan and 4 co-authors. Institution: Department of Social and Preventive Medicine, Center for Public Health, Medical University of Vienna, Vienna, Austria. Major MEDLINE topics: Obesity, Weight Loss, Incretins, Anti-Obesity Agents. Cited 1 times so far (Crossref); 37 references. The full text is freely available (open access, CC BY-NC 4.0).

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Aim

This study aims to examine weight‐loss history and pre‐treatment concerns, and their associations with current functioning and well‐being in adults undergoing incretin‐based pharmacotherapy for obesity. Materials and Methods This cross‐sectional study analysed 411 adults treated with three different incretin‐based medications. Demographics, previous weight‐loss interventions, barriers to earlier attempts, reasons for initiating incretin therapy, treatment characteristics and Treatment‐Related Impact Measure for Weight (TRIM‐Weight) total scores were assessed. Associations between specific pre‐treatment concerns and functioning and well‐being were analysed using univariate models and a multivariable regression model that adjusted for treatment related variables.

Results

Participants had a median age of 39 years (IQR 33–47), 79.1% were women, and the median BMI was 36.3 kg/m 2 (IQR 32.2–42.3). The median TRIM‐Weight total score was 68.2 (IQR 64.0–73.4). Most respondents (95.1%) had attempted weight loss, typically through combined diet and physical activity (71.8%), intermittent fasting (69.6%) and digital tracking tools (65.7%). In fully adjusted models, fear of side effects ( β = −3.53, 95% CI −4.05 to −3.01), concerns about cost ( β = −0.92, 95% CI −1.37 to −0.47) and injection anxiety ( β = −0.67, 95% CI −1.16 to −0.18) were associated with lower functioning and well‐being. Doubts regarding effectiveness showed a small positive association ( β = 0.61, 95% CI 0.03–1.19).

Conclusion

Among retrospectively reported pre‐treatment concerns, fear of side effects, treatment costs and injection anxiety were most strongly associated with lower functioning and well‐being, whereas moral or psychosocial concerns showed no independent associations after multivariable adjustment.

Subjects

MeSH terms (MEDLINE)

ObesityWeight LossIncretinsAnti-Obesity AgentsCross-Sectional StudiesIntermittent FastingExerciseQuality of LifeSurveys and QuestionnairesSemaglutideTirzepatideBody WeightInjections, SubcutaneousAnxietyFees, PharmaceuticalHumansMaleFemaleAdultMiddle AgedTreatment OutcomeMorals

Author keywords

incretin therapypatient reported outcomesemaglutidetirzepatide obesitywell‐being

Substances

IncretinsSemaglutideTirzepatideAnti-Obesity Agents

Authors and institutions

  • Department of Social and Preventive Medicine, Center for Public Health, Medical University of Vienna, Vienna, Austria.
  • Department of Epidemiology, Center for Public Health, Medical University of Vienna, Vienna, Austria.
  • Exercise Physiology, Training & Training Therapy Research Group, Institute of Human Movement Science, Sport and Health, University of Graz, Graz, Austria.
  • Division of Endocrinology and Diabetology, Department of Internal Medicine, Medical University of Graz, Graz, Austria.

ORCID profiles: Ali Kapan, Thomas Waldhör, Othmar Moser

Cite

APA

Kapan, A., Brandl, T., Waldhör, T., Moser, O., & Felsinger, R. (2026). Pre‐Treatment Concerns and Their Association With Functioning and Well‐Being During Incretin‐Based Therapy: A Cross‐Sectional Study. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.70599

Vancouver

Kapan A, Brandl T, Waldhör T, Moser O, Felsinger R. Pre‐Treatment Concerns and Their Association With Functioning and Well‐Being During Incretin‐Based Therapy: A Cross‐Sectional Study. Diabetes, Obesity and Metabolism. 2026. doi:10.1111/dom.70599

BibTeX
@article{Kapan2026,
  author = {Kapan, Ali and Brandl, Tobias and Waldhör, Thomas and Moser, Othmar and Felsinger, Richard},
  title = {Pre‐Treatment Concerns and Their Association With Functioning and Well‐Being During Incretin‐Based Therapy: A Cross‐Sectional Study},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2026},
  doi = {10.1111/dom.70599}
}
Start for free →